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Abstract
Background: Paclitaxel-based regimens are frequently associated with the development of peripheral neuropathy.
The autonomous nervous system (ANS) effects, however, of this chemotherapeutic agent remain unexplored.
Methods: We investigated a group of 31 female patients with ovarian cancer receiving treatment with paclitaxel
and carboplatin, as well as a group of 16 healthy age- and gender-matched healthy volunteers. All study
participants completed a questionnaire and were assessed neurophysiologically at three time points (baseline, 3–4
months and 6–8 months following the onset of chemotherapy). The evaluation of the ANS included assessment of
the adrenergic cardiovascular function (orthostatic hypotension-OH), parasympathetic heart innervation (30/15 ratio)
and sympathetic skin response (SSR).
Results: At the 3–4 months ANS assessment, 19.2 % of the patients had systolic OH and the same percentage had
diastolic OH, but at the 6–8 months evaluation no patient had systolic OH and only 13.8 % had diastolic OH. The
values of the 30/15 ratio were significantly reduced at both time points, whereas the SSR was not affected.
Conclusions: Combined paclitaxel and carboplatin chemotherapy is associated with significant effects on the
parasympathetic heart innervation and occasionally with effects on the adrenergic cardiovascular reaction. The SSR
remained unaffected. Physicians should be alert to the possibility of these treatment-emergent side effects, so as to
monitor ANS parameters and introduce treatment modifications accordingly. Our findings however, should be
validated in larger cohorts.
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Background
Paclitaxel is commonly used as first-line chemotherapy
for advanced ovarian cancer and as adjuvant treatment,
in combination with cisplatin or carboplatin, for residual
disease. Taxanes (paclitaxel and docetaxel) are associated
with numerous side effects, particularly including neuro-
toxic phenomena [1] . For instance, severe peripheral
neuropathy is known to occur in patients receiving
cumulative doses of around 1000 mg/m2 paclitaxel
and 400 mg/m2 docetaxel [2]. In recent years, research
interest focused on maximizing the therapeutic efficacy of
paclitaxel, while minimizing the associated side effects.
Despite these efforts, primarily sensory and occasionally
sensorimotor [3, 4] peripheral neuropathy occurs in 59 to
78 % of treated patients [5–7].
Generalized peripheral neuropathies are frequently
accompanied by autonomous nervous system (ANS)
dysfunction [8]. However, it is currently unknown
whether paclitaxel or its combination with carboplatin
affects the ANS and whether paclitaxel-induced neur-
opathy comprises autonomic phenomena, as well.
The present study was designed to address this issue
and investigate the effects of the combination of pacli-
taxel and carboplatin chemotherapy on the ANS. From a
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clinical point of view, paclitaxel is occasionally associ-
ated with hypotension, bradycardia and hypertension.
Accordingly, we investigated the impact of paclitaxel on
the sympathetic and parasympathetic innervation of the
heart and performed additional tests to assess sudomo-
tor function (i.e. Sympathetic Skin Response–SSR) and
somatic peripheral nerve fibers (i.e. sensory and motor
Nerve Conduction Velocities–NCVs). It should be noted
that the above tests are easily performed in the context
of a routine clinical neurophysiological examination and
were employed to increase the utility and relevance of
our findings to every-day clinical practice.
Methods
Patients’ selection
Thirty-one female patients with ovarian cancer receiving
treatment with paclitaxel and carboplatin entered the
study. The therapeutic regimen involved six sessions of
combined chemotherapy administered every 3 weeks in
the following manner: paclitaxel was given at a dose of
175 mg/m2 as a 3-h i.v. infusion (with monitoring of blood
pressure and pulses every hour) and carboplatin was
administered at a dose estimated from the formula Dose
(mg) = target AUC (mg/ml.min) x [GFR (ml/min) + 25]. A
control group comprising 16 age- and gender-matched
healthy volunteers was also included.
Exclusion criteria included age <18 years, history of
peripheral neuropathy, intake of drugs affecting the
ANS, alcohol abuse, diabetes mellitus and previous
exposure to chemotherapy.
The clinical protocol was approved by the Institutional
Review Board of ‘Papageorgiou’ Hospital and the Bioethics
Committee of the Aristotle University of Thessaloniki.
All study participants provided written informed con-
sent for participating in the study, which was in
accordance with the ethical standards laid in the 1964
Declaration of Helsinki.
Procedures
For the assessment of ANS function, participants com-
pleted a questionnaire and underwent neurophysio-
logical examination of the ANS and motor and sensory
NCVs, by the same neurologist. All tests took place in
the morning, in a quiet environment. Study participants
were asked to fast, refrain from smoking and exercise
for the previous 12 h and sleep comfortably 8 h the
night before. Patients had to have no symptoms of
sepsis and were examined at least 7 days after their
last cycle of chemotherapy. Patients underwent ANS
testing and completed an ANS and neuropathy ques-
tionnaire (Additional file 1) at three time points: at
baseline (n = 31), 3–4 months (n = 26) and 6–8 months
(n = 29) after the first chemotherapy cycle. Healthy
volunteers (n = 16) were examined once.
Questionnaire
All study participants completed the same questionnaire
at all visits. The total number of positive responses for
the ANS before and after chemotherapy administration
was used as a subjective measure of the effect of pacli-
taxel in combination with carboplatin on the patients’
quality of life.
Neurophysiological examination
The assessment of the ANS and somatic peripheral nerve
fibers was performed as previously reported [9]. Briefly,
ANS testing included the assessment of the parasympa-
thetic heart innervation by measuring alterations in car-
diac rhythm in response to changes in posture from the
supine to the erect position, known as the 30/15 ratio.
The adrenergic cardiovascular function was assessed by
measuring alterations in blood pressure (BP) in response
to changes in posture from the supine to the standing pos-
ition. Orthostatic hypotension (OH) was defined as a sys-
tolic BP (SBP) drop of ≥20 mmHg and/or a diastolic BP
(DPB) drop of ≥10 mmHg within 3 min of active standing
[10]. Sympathetic sudomotor function was evaluated using
the SSR test [11]. NCVs were also examined in order to
diagnose or monitor the evolution of a sensory and/or
motor neuropathy, the severity of which was determined
on the basis of the Common Terminology Criteria for Ad-
verse Events (NIH-NCI, 2003, version 3.0).
Statistical analysis
Categorical parameters were presented as counts with
corresponding percentages, while for continuous parame-
ters various measures were used (median plus range and/or
mean plus range or standard deviation (SD)). Variable
distributions were tested for normality by the use of
Kolmogorov-Smirnov test. Abnormal values among the
evaluation time points (baseline, 3–4 and 6–8 months)
were tested for marginal homogeneity using the McNe-
mar’s test [12]. Measurements between baseline and post-
treatment assessments were compared by the use of
Wilcoxon signed ranks tests [13]. The Mann-Whitney test
[14] was used for the comparison of the median 30/15 ratio
with neuropathy grade (0–I vs. II–III). Progression-free
survival (PFS) was measured from the time of initiation of
first-line treatment until verified disease progression, death
or last contact (whichever occur first), while, overall sur-
vival (OS) was measured from the time of initiation of first-
line treatment until death from any cause or date of last
contact. All tests were two-sided with level of significance
set at 5 %. The SPSS software (version 15.0, IBM Corpor-
ation, Armonk, NY, USA) was used for statistical analysis.
Results and discussion
The mean age in the patient group was 52 years (range
38–74) and in the healthy control group 54 years (range
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28–77). Five patients decided not to participate for
personal reasons in the 3–4 month assessment and two in
the 6–8 month assessment without, however, interrupting
or modifying the overall treatment schedule. Table 1 sum-
marizes the number of chemotherapy cycles, median dose
intensities and cumulative doses for the two administered
drugs while Table 2 includes survival data (progression-
free and overall survival) for the patient group.
ANS assessments
Autonomous nervous system assessment results did not
differ significantly between the patient and healthy
control groups at baseline.
At the 3–4 months ANS assessment, the number of
patients with orthostatic hypotension (OH) increased
compared to baseline. After 3 min of active standing,
reduction in systolic blood pressure (SBP) of ≥20 mmHg
wasn’t observed in any patient at baseline but in five
patients (19.2 %) at 3–4 months. A reduction in diastolic
blood pressure (DBP) of ≥10 mmHg was observed in
two patients (7.7 %) at baseline but on five patients (19.2
%) at the 3–4 months evaluation. These differences,
however, failed to reach statistical significance possibly
as a result of a type II error due to small sample size.
The values of the 30/15 ratio were significantly reduced
at the 3–4 months assessment compared to baseline
(Wilcoxon signed ranks test, P = 0.016) whereas the SSR
was not affected (Table 3).
At the 6–8 month evaluation, 26 patients (89.7 %)
among the 29 patients, who were examined, had com-
pleted chemotherapy. The results of the orthostatic
hypotension testing were clearly improved compared to
the 3–4 month assessment. Thus, no patient had a
reduction of ≥20 mmHg after 3 min of active standing at
the 6–8 months evaluation, similarly to baseline. Four
patients (13.8 %) had a reduction in DBP of ≥10 mmHg
after 3 min of active standing compared to three patients
(9.7 %) at baseline. The values of the 30/15 ratio were
significantly reduced compared to baseline (P = 0.002)
whereas the SSR wasn’t affected (Table 4).
On an individual patient level, the incidence of abnor-
mal 30/15 ratio varied longitudinally as follows: three
patients had abnormal values at both baseline and the 3–4
months time points whereas one patient had an abnormal
baseline value which subsequently normalized. Twelve
patients had normal values at baseline, which became
abnormal at 3–4 months (McNemar’s test, P = 0.003),
whereas ten patients had consistently normal values. One
patient had abnormal value at both baseline and the 6–8
months time point and two patients had abnormal
baseline values, which subsequently normalized. Twelve
patients had normal values at baseline, which became ab-
normal at 6–8 months (McNemar’s test, P = 0.013),
whereas 14 patients had consistently normal values.
At the 6–8 months evaluation, four patients were still
on treatment or <1 month after treatment completion
and 25 patients had completed treatment more than a
month earlier. These two groups were not significantly
different in any of the examined ANS parameters. In the
latter group of 25 patients, there were no significant
differences in ANS parameters between the 3–4 month
and the 6–8 month evaluation.
Assessment of the 30/15 ratio according to the grade of
sensory neuropathy
With regard to the severity of sensory neuropathy,
patients were dichotomized into two groups: those with
no sensory neuropathy or asymptomatic neuropathy
only (grade 0–I) and those with higher grade sensory
neuropathy (grade II–III). No differences in the median
30/15 ratio were found between the two groups of
patients at either post-treatment evaluation (Table 5).
Questionnaire results
Regarding the incidence of positive responses in the
ANS dysfunction questionnaire, there were no signifi-
cant differences in the distribution of positive answers
between healthy volunteers and patients at the base-
line evaluation. However, the mean (2.35) and median
(2) number of positive answers was higher at the 3–4
months (Wilcoxon signed ranks test, P = 0.002) but
Table 1 Number of chemotherapy cycles, median dose
intensities and median cumulative doses. Combined paclitaxel
and carboplatin chemotherapy was administered to the 31
ovarian cancer patients
Total number of cycles administered 195
Median number of cycles (range) 6 (4–8)
Median cumulative dose (mg) (range)
Paclitaxel 1737 (1108–2664)
Carboplatin 3915 (1550–6220)
Median dose intensity (mg/m2/week) (range)
Paclitaxel 164.3 (109.2–247.8)
Carboplatin 396.0 (141.1–558.9)
Table 2 Survival data for the patient group (n = 31)
Progression-free survival (PFS)
Progressions [n (%)] 14 (45.2)
3-year PFS (%) 61.3
Range (months) 6.2–47.8
Overall survival (OS)
Deaths [n (%)] 9 (29.0)
3-year OS (%) 79.8
Range (months) 14.9–52.9
Median follow-up (months) 39.7
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not the 6–8 months (mean = 1.66 and median = 2, P = 0.33)
evaluations compared to baseline (mean = 1.29 and
median = 1).
The present study was designed to investigate the
ANS effects of paclitaxel in conjunction with carboplatin
in patients with ovarian cancer. It is concluded that the
intravenous administration of paclitaxel at a dose of 175
mg/m2 in combination with carboplatin affects the sym-
pathetic heart innervation, resulting in primarily systolic
orthostatic hypotension during the treatment period. In
addition, this chemotherapeutic regimen affects para-
sympathetic heart innervation both during treatment, as
well as during the period ensuing after the last che-
motherapy session. Finally, this drug combination has
minimal effects on the function of the ANS beyond the
cardiovascular system.
In our cohort, no patient had systolic orthostatic
hypotension at baseline but five out of 26 patients
developed this side effect at the 3–4 month assessment.
Interestingly, at the 6–8 month evaluation, when the
vast majority of patients had completed treatment more
than a month earlier, no subject had evidence of
systolic orthostatic hypotension. These observations
suggest that the effect of combined paclitaxel and
carboplatin chemotherapy on the sympathetic heart
innervation is short lived and confined during the treat-
ment period only. It should be noted that in a study on
the effects of oxalplatin on sympathetic heart innerv-
ation in patients with colorectal cancer, the effects were
not transient [9]. This difference may possibly be attrib-
uted to the mean age of patients participating in the
present study being lower.
The ANS effects of combined paclitaxel and carbopla-
tin chemotherapy were even more evident on the para-
sympathetic heart innervation, as the 30/15 ratio was
significantly affected at all time points following the
onset of treatment (i.e both at the 3–4 and 6–8 months
assessments). However, this protracted decrease of the
30/15 ratio was not associated with the severity of a
chemotherapy-induced sensory neuropathy.
The existing literature on the cardiotoxicity of paclitaxel
suggests that transient, asymptomatic bradycardia may
occur in up to 29 % of treated patients [15]. Cardiac dys-
function may also occur due to combination of paclitaxel
with other chemotherapeutics, such as the monoclonal
antibody trastuzumab [16] or epirubicin [17, 18]. It is well
known that the administration of paclitaxel in conjunction
with doxorubicin in patients with breast cancer is cardio-
toxic [19–22]. However, in our study none of the patients
received such combinations of chemotherapeutic regimens.
It could be argued that the cardiotoxicity observed in
the present study may be due, at least in part, to carbopla-
tin, the co-administered chemotherapeutic agent. Several
publications have reported potential subtle cardiotoxic
effects of carboplatin when administered in combination
with paclitaxel [23–25].
The fact that SSR remained unaffected, despite the devel-
opment of a primarily sensory and to a lesser extent motor
peripheral neuropathy in a sizeable proportion of our
patients, is not surprising. It is well known that when fast-
conducting, large-diameter myelinated fibers are affected
(for instance in cases of carpal tunnel syndrome), the SSR
remains intact and is not regarded diagnostically useful in
this particular setting [26].
Table 3 Three to four months evaluation of 30/15 ratio and sympathetic Skin Response (SSR)
Baseline (n = 31) 3–4 months evaluation (n = 26) Wilcoxon signed ranks test
Mean (SD) Median (Range) Mean (SD) Median (Range) P-value
30/15 ratio 1.13 (0.09) 1.10 (1.00–1.43) 1.10 (0.20) 1.03 (0.89–1.94) 0.016
SSR
Upper limbs 1.46 (0.34) 1.38 (1.10–3.01) 1.61 (0.45) 1.53 (1.10–3.01) 0.17
Lower limbs 2.22 (0.42) 2.20 (1.60–3.13) 2.27 (0.47) 2.25 (1.60–3.13) 0.74
SSR sympathetic skin response
Significant p-values are shown in bold
Table 4 Six to eight months evaluation of 30/15 ratio and sympathetic Skin Response (SSR)
Baseline (n = 31) 6–8 months evaluation (n = 29) Wilcoxon signed ranks test
Mean (SD) Median (Range) Mean (SD) Median (Range) P-value
30/15 ratio 1.13 (0.09) 1.10 (1.00–1.43) 1.07 (0.09) 1.06 (0.94–1.30) 0.002
SSR
Upper limbs 1.46 (0.34) 1.38 (1.10–3.01) 1.50 (0.41) 1.46 (1.00–3.01) 0.58
Lower limbs 2.22 (0.42) 2.20 (1.60–3.13) 2.13 (0.41) 2.08 (1.59–3.13) 0.74
SSR sympathetic skin response
Significant p-values are shown in bold
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The findings from the ANS evaluations corresponded
temporally to increases in positive responses in the ques-
tionnaire completed by the patients at 3–4 and 6–8
months following the onset of chemotherapy. At baseline,
the mean number of positive responses was 1.13, increas-
ing to a maximum of 2.35 positive responses at the 3–4
months assessment and dropping to a mean of 1.66 at the
6–8 months time point, when the majority of patients had
completed the treatment regimen. It is conceivable, how-
ever, that the increase in positive responses may simply
reflect the general malaise induced by chemotherapy,
rather than being the clinical expression of treatment side
effects specifically induced on the ANS.
Conclusions
The present study highlights the fact that combined
paclitaxel and carboplatin chemotherapy for ovarian
cancer is associated with significant effects on the sym-
pathetic and parasympathetic heart innervation, whereas
the SSR remains relatively untouched. Physicians caring
for patients with ovarian cancer should be alert to the
possibility of these treatment-emergent side effects, so as
to monitor ANS parameters (BP, cardiac rhythm and
their alterations upon standing) and introduce treatment
modifications accordingly. Our findings however, should
be validated in larger cohorts.
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